MeiraGTx to Present at Upcoming Healthcare Conferences

LONDON and NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc MGTX, a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Evercore ISI 2^nd Annual HealthCONx Conference in Boston, MA on Tuesday, December 3, 2019 at 8:20 a.m. ET.

Dr. Forbes will also participate in a fireside chat at Piper Jaffray's 31^st Annual Healthcare Conference on Thursday, December 5, 2019 at 10:30 a.m. ET in New York, NY.

A live webcast of each presentation will be available on the Investors page of the Company's website at www.investors.meiragtx.com. A replay of the webcasts will be available for approximately 30 days following the presentations.

About MeiraGTx

MeiraGTx MGTX is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx's initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, neurodegenerative diseases and severe forms of xerostomia and xerophthalmia. Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

For more information, please visit www.meiragtx.com.

Contacts



Investors:

MeiraGTx

Elizabeth Broder

(646) 860-7983

Investors@meiragtx.com

or

Media:

W2O pure

Christiana Pascale

(212) 257-6722

cpascale@purecommunications.com